Quantitative score of HLA diversity
Quantifying HLA allelic diversity through percentile scores and additional parameters improves the prediction of patient responses to immune checkpoint inhibitors, addressing the complexity of HLA typing and heterozygosity analysis in treatment outcomes.
Patent Information
- Application Number
- JP2024147700
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-04-05
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-21
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing methods for determining HLA class I gene typing are complex due to high allelic diversity, making it difficult to predict patient responses to treatments like immune checkpoint inhibitors, and traditional HLA heterozygosity analysis does not accurately predict treatment outcomes.
A method to quantify HLA allelic diversity by calculating percentile scores for alignment of HLA allele pairs, considering additional parameters like expression levels and tumor mutational burden, to predict patient response to treatments.
The method provides accurate biomarkers for predicting patient response to immune checkpoint inhibitors, differentiating patient groups with statistically significant survival differences, enhancing treatment efficacy prediction.
Smart Images

Figure 2024163150000002 
Figure 2024163150000003 
Figure 2024163150000004
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 830,297, filed April 5, 2019, the disclosure of which is incorporated herein by reference in its entirety.
[0002] background Field The present disclosure relates to HLA allelic diversity and quantifying HLA allelic diversity. [Background technology]
[0003] 2. Description of Related Art The human leukocyte antigen (HLA) system or complex is a complex of genes that encodes the major histocompatibility complex (MHC) proteins in humans. The major histocompatibility complex (MHC) is a set of cell surface proteins essential for the adaptive immune system to recognize foreign molecules in vertebrates, which determines histocompatibility. The main function of MHC molecules is to bind antigens from pathogens and display them on the cell surface for recognition by appropriate T cells. MHC molecules are responsible for regulating the immune system in humans. MHC determines the suitability of donors for organ transplants, as well as susceptibility to autoimmune diseases through cross-reactive immunity. Thus, HLA plays an important role in infectious diseases, autoimmune diseases, and cancer. Summary of the Invention [Means for solving the problem]
[0004] Abstract In some embodiments, a method of quantifying diversity of at least one HLA allele pair in a subject comprises obtaining DNA sequences of one or more HLA allele pairs in the subject, comparing the DNA sequences of the one or more HLA allele pairs to obtain an alignment score, obtaining a distribution of the alignment scores of the one or more HLA allele pairs, and determining a percentile score of the at least one HLA allele pair relative to the distribution of alignment scores of all HLA allele pairs.
[0005] In some embodiments, the method of quantifying diversity of at least one HLA allele pair in a subject further comprises comparing the percentile score to a first predetermined threshold.
[0006] In some embodiments of the methods of quantifying the diversity of at least one HLA allele pair in a subject, the at least one HLA allele pair comprises any pair of HLA A, B, C, E, F, G, H, J, K, L, DP, DQ, and DR alleles.
[0007] In some embodiments of the methods of quantifying the diversity of at least one HLA allele pair in a subject, if the percentile score is equal to or greater than a first predetermined threshold, the subject is recommended a first treatment.
[0008] In some embodiments of the methods of quantifying diversity of at least one HLA allele pair in a subject, if the percentile score is less than a first predetermined threshold, the subject is recommended a second treatment.
[0009] In some embodiments, the method for quantifying the diversity of at least one HLA allele pair in a subject further comprises: determining the expression level of one or more HLA allele pairs; obtaining the expression level score of at least one HLA allele pair relative to the expression level of one or more HLA allele pairs; determining the weighted percentile score of at least one HLA allele pair relative to the distribution of the alignment score of one or more HLA allele pairs based on the expression level score of at least one HLA allele pair; and comparing the weighted percentile score with a second predetermined threshold.In some embodiments, if the weighted percentile score is equal to or greater than the second predetermined threshold, the subject is recommended to receive the first treatment.
[0010] In some embodiments, if the weighted percentile score is less than a second predetermined threshold, the subject is recommended for a second treatment.
[0011] In some embodiments, the first predetermined threshold is about 75%.
[0012] In some embodiments, the second predetermined threshold is about 75%.
[0013] In some embodiments, the first treatment comprises an ICI.
[0014] In some embodiments, the second treatment comprises a non-ICI.
[0015] In some embodiments, if the first predetermined threshold is 50%, the subject is further recommended a first additional treatment.
[0016] In some embodiments, if the second predetermined threshold is 50%, the subject is further recommended a second additional treatment.
[0017] In some embodiments, the expression level is an RNA expression level, a protein expression level, or both.
[0018] In some embodiments of the methods of quantifying the diversity of at least one HLA allele pair, the quantifying is repeated over time to determine whether there is a change in the percentile score relative to a first predetermined threshold.
[0019] In some embodiments of the methods of quantifying the diversity of at least one HLA allele pair, the quantification is repeated over time to determine whether there is a change in the percentile score relative to the second predetermined threshold.
[0020] In some embodiments of the methods of quantifying the diversity of at least one HLA allele pair, the quantifying comprises an assessment of TCR clonality.
[0021] In some embodiments, a method of determining the predicted efficacy of a cancer treatment in a patient comprises calculating a hazard ratio for an HLA allele pair in the patient, where the hazard ratio reflects the allelic diversity of the HLA allele pair in the patient, and comparing the hazard ratio to a predetermined threshold, where a hazard ratio above the predetermined threshold indicates that the patient is predicted to have a high efficacy against the cancer treatment and a hazard ratio below the predetermined threshold indicates that the patient is predicted to have a low efficacy against the cancer treatment.
[0022] In some embodiments, the method of determining the predicted efficacy of a cancer treatment in a patient further comprises measuring the patient's tumor burden score as a factor in determining the efficacy of the cancer treatment and comparing the tumor burden score to a predetermined threshold. [Brief description of the drawings]
[0023] [Figure 1]Figures 1A-1C show the amino acid diversity at each position for proteins encoded by HLA-A (Figure 1A), HLA-B (Figure 1B) and HLA-C (Figure 1C), respectively. On the graph, lower scores indicate greater diversity. The numbers at the top of Figure 1A indicate the various protein domains of the HLA proteins based on amino acid position.
[0024] [Figure 2-1] 2A shows a graph of the results of determining HLA diversity scores in combination with HLA heterozygosity by methods known in the art. The X-axis shows the timeline in days and the Y-axis shows overall survival (1=100%).
[0025] [Figure 2-2] 2B shows a graph of the results of the determination of HLA diversity score in combination with HLA heterozygosity according to one embodiment of the method of quantifying HLA diversity according to the present disclosure, where the X-axis shows the timeline in days and the Y-axis shows overall survival (1=100%).
[0026] [Figure 3-1] 3A shows a graph of the results of the determination of HLA heterozygosity and HLA diversity score in combination with TMB by methods known in the art. The X-axis shows the timeline in days and the Y-axis shows overall survival (1=100%).
[0027] [Figure 3-2] 3B shows a graph of the results of determining HLA heterozygosity and HLA diversity score in combination with TMP according to one embodiment of the method of quantifying HLA diversity according to the present disclosure. The X-axis shows the timeline in days and the Y-axis shows overall survival (1=100%).
[0028] [Figure 4] Figure 4 shows a graph of the correlation between TMB and overall survival. The X-axis shows the timeline in days and the Y-axis shows overall survival (1=100%). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0029] The embodiments of the present disclosure relate to systems and methods for quantifying HLA allele variant diversity in patient-derived biological samples. In some embodiments, the systems and methods are for quantifying HLA diversity in solid tissue or circulating tumor DNA samples. In some embodiments, the systems and methods are for quantifying HLA diversity in solid tissue or circulating tumor DNA samples that predicts patient responsiveness to a therapy for treating such indications. In some embodiments, the systems and methods are for quantifying HLA diversity in solid tissue or circulating tumor DNA samples that predicts patient responsiveness to an anti-tumor therapy. In some embodiments, the systems and methods are for quantifying HLA diversity in solid tissue or circulating tumor DNA samples that predicts patient responsiveness to an immune checkpoint inhibitor therapy.
[0030] As discussed below, each HLA allele is composed of various domains. Some embodiments relate to systems and methods for comparing the diversity of HLA domains of patients, to calculate the variation between each domain for each HLA allele. For example, one patient with a tumor may have two HLA alleles whose domains are 95% identical. Another patient with a tumor may have two HLA alleles whose domains are 15% identical. In one embodiment, the system may determine that a patient with HLA allele variants that are only 15% identical and more diverse from each other may have a higher chance of successful cancer treatment compared to a tumor patient with less diverse HLA allele domains. In one example, the cancer treatment may be a CAR-T treatment, in which patient T cells are taken, genetically modified, and attached to the tumor. Patients with a greater diversity of HLA allele variants may have a more successful CAR-T treatment compared to patients with less diversity between HLA alleles.
[0031] HLA class I genes are components of the human major histocompatibility complex (MHC). Class I genes consist of three classical genes, HLA-A, HLA-B and HLA-C, which code for the major transplantation antigens, and seven non-classical class I genes, HLA-E, HLA-F, HLA-G, HLA-H, HLA-J, HLA-K and HLA-L.
[0032] The HLA complex is located on the short arm of chromosome 6. Genes belonging to HLA class I code for MHC class I proteins, and genes belonging to HLA class II code for MHC class II proteins. Each HLA class I gene has eight exons, the first seven of which code for different parts of the protein (exon 1 - leader peptide, exon 2 - alpha 1 domain, exon 3 - alpha 2 domain, exon 4 - alpha 3 domain, exon 5 - transmembrane region, exon 6 - cytoplasmic tail, exon 7 - cytoplasmic tail). Exons 2 and 3 are the most important, since they code for the binding core of the HLA molecule and are also the most polymorphic regions (Figures 1A, 1B, and 1C).
[0033] Classical HLA class I genes code for polymorphic cell surface proteins expressed on most nucleated cells. The natural function of these proteins is to bind and present a diverse set of peptide fragments from intracellularly processed antigens to the T cell antigen receptor (TCR). Thus, the peptide-binding capacity of MHC molecules facilitates immune recognition of intracellular pathogens and modified self-proteins. Thus, by increasing the peptide repertoire of the TCR, polymorphism of MHC molecules plays an important role in the host's immune response potential. On the other hand, MHC polymorphism exerts an immunological burden on hosts transplanted with allogeneic tissues. As a result, mismatch of HLA class I molecules is one of the main causes of allograft rejection and graft-versus-host disease, and the level of HLA matching between tissue donors and recipients is the main factor in the success of allogeneic tissue and bone marrow transplantation. Therefore, being able to determine the "type" of HLA class I genes of candidate organ donors and recipients is of great medical significance.
[0034] HLA class I histocompatibility antigens for patient-donor matching are traditionally determined by serological typing. Biochemical and molecular techniques have revealed that HLA class I polymorphism is much greater than previously recognized by traditional methods.
[0035] The number of newly identified HLA alleles has been increasing over time, with nearly 15,000 HLA class I alleles and over 5,000 HLA class II alleles as of 2018. To date, approximately 4,638 different HLA-A allele sequences, 5,590 different HLA-B allele sequences, and 4,374 different HLA-C allele sequences have been identified. These different allele sequences code for approximately 3,172 HLA-A proteins, 3,923 HLA-B proteins, and 2,920 HLA-C proteins. This high level of allelic diversity complicates typing of HLA class I genes. Thus, HLA typing at the nucleic acid level is a very challenging task. The diversity of alleles within any one gene means that a very large number of probes need to be developed if hybridization-based tests are used for typing. Furthermore, the general applicability of DNA typing methods for HLA genes relies on the design of primers that enable locus-specific amplification of a single HLA gene.
[0036] Quantification of HLA diversity In some embodiments, systems and methods are provided herein for quantifying the diversity of HLA alleles.In some embodiments, diversity scores are calculated for all pairwise HLA alleles by calculating percentiles of the alignment scores of a given pair of HLA alleles in the distribution of all pairwise alignment scores.
[0037] In some embodiments, a method of quantifying diversity of at least one HLA allele pair in a subject comprises obtaining DNA sequences of one or more HLA allele pairs in the subject, comparing the DNA sequences of the one or more HLA allele pairs to obtain an alignment score, obtaining a distribution of the alignment scores of the one or more HLA allele pairs, and determining a percentile score of the at least one HLA allele pair relative to the distribution of alignment scores of all HLA allele pairs.
[0038] In some embodiments, the method of quantifying the diversity of at least one HLA allele pair further comprises comparing the percentile score to a first predetermined threshold.
[0039] In some embodiments of the methods of quantifying the diversity of at least one HLA allele pair, the at least one HLA allele pair comprises any pair of HLA A, B, C, E, F, G, H, J, K, L, DP, DQ, and DR alleles.
[0040] In some embodiments of the methods of quantifying the diversity of at least one HLA allele pair, the at least one HLA allele pair comprises a combination of alleles from any row and alleles from any stage in Table 1. Table 1 - Allele pair combinations [Table 1]
[0041] In some embodiments, any of the allele combinations listed in Table 1 can be combined with one or more additional parameters in one embodiment of the methods of quantifying HLA diversity provided herein. Non-limiting examples of additional parameters include RNA and / or protein expression levels of HLA alleles, HLA zygosity, familial inheritance, hereditary inheritance, Mendelian inheritance, non-Mendelian inheritance, other genetic associations and correlations, such as tumor mutation burden (TMB), neoantigen load, microsatellite instability, tumor microenvironment, T cell receptor repertoire diversity.
[0042] In some embodiments, the one or more additional parameters include the mutational burden of the tumor and / or cancer in one embodiment of the method of quantifying HLA diversity provided herein. As used herein, "mutational burden of the tumor and / or cancer" (also referred to herein as "mutational burden" or "tumor burden score" or TMB) refers to the total number of somatic coding mutations in the tumor and / or cancer genome.
[0043] Without being limited to any particular theory, it is believed that a higher TMB increases the probability of neoantigen recognition by cytotoxic T cells.
[0044] In some embodiments, the one or more additional parameters include patient age, sex, tumor stage, cancer type, patient infection history, and cancer treatment regimen.
[0045] In some embodiments of the methods of quantifying diversity of at least one HLA allele pair, if the percentile score is equal to or greater than a first predetermined threshold, the subject is recommended a first treatment.
[0046] As used herein, "percentile score" is defined as the measure that indicates the value that a given percentage of observations in a group of observations falls below.For example, if the alignment of a pair of HLA alleles or allele domains produces a percentile score of 95, the pair of HLA alleles is more similar to each other than 95% of all pairs of HLA alleles or domains in the group of alleles analyzed.On the other hand, if the alignment of a pair of HLA alleles produces a percentile score of 5, the pair of HLA alleles or domains is more similar to each other than only 5% of all pairs of HLA alleles or domains in the group of alleles analyzed.
[0047] As used herein, "predetermined threshold" refers to a threshold value based on HLA percentile score.Predetermined threshold can vary based on an embodiment of the method for quantifying HLA diversity.For example, predetermined threshold can vary according to the number of additional parameters included in an embodiment of the method for quantifying HLA diversity.
[0048] In some embodiments, the subject is a human. In some embodiments, the methods and systems provided herein can be extrapolated to other organisms. Non-limiting examples include non-human primates, rats, mice, dogs, cats, guinea pigs, cows, etc.
[0049] Non-limiting examples of tumors / cancers include solid tumor malignancies such as breast adenocarcinoma, pancreatic adenocarcinoma, lung cancer, prostate cancer, glioblastoma multiforme, hormone refractory prostate cancer, colon cancer, non-small cell lung cancer (NSCLC), anaplastic astrocytoma, bladder cancer, sarcoma, ovarian cancer, rectal hemangiopericytoma, pancreatic cancer, advanced cancer, colon, gastric, pancreatic, ovarian cancer, and melanoma. The tumors / cancers include any neoplasm involving the brain, including but not limited to pancreatic cancer, colon cancer, bladder cancer, hematological malignancies, squamous cell carcinoma, breast cancer, glioblastoma, or astrocytoma (e.g., neutrophilic astrocytoma, diffuse astrocytoma, plasmacytoma, and brain stem cell tumor), glioblastoma (e.g., glioblastoma multiforme), meningioma, other gliomas (e.g., ependymoma, oligodendroglioma, and mixed glioma), and other brain tumors (e.g., pituitary tumor, craniopharyngeal tumor, germ cell tumor, pineal region tumor, medulloblastoma, and primary CNS lymphoma). In some embodiments, the tumor / cancer is associated with one or more types of tumor / cancer as set forth herein.
[0050] In some embodiments, the first treatment comprises an immune checkpoint inhibitor (ICI). In some embodiments, the ICI stimulates cytotoxic lymphocyte activity against tumor and / or cancer cells.
[0051] In some embodiments, the first treatment comprises an ICI selected from the group consisting of a PD-1 inhibitor, a PDL-1 inhibitor, and a CTLA-4 inhibitor.
[0052] In some embodiments, the first treatment comprises one or more ICIs selected from the group consisting of a PD-1 inhibitor, a PDL-1 inhibitor, and a CTLA-4 inhibitor.
[0053] In some embodiments, the first treatment comprises a combination of ICIs selected from the group consisting of a PD-1 inhibitor, a PDL-1 inhibitor, and a CTLA-4 inhibitor.
[0054] In some embodiments, the first treatment comprises an ICI selected from the group consisting of pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo) atezolizumab (Tecentriq), avelumab (Bavencio), durvalumab (Imfinzi), and ipilimumab (Yervoy).
[0055] In some embodiments, the first treatment comprises one or more ICIs selected from the group consisting of pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo) atezolizumab (Tecentriq), avelumab (Bavencio), durvalumab (Imfinzi) and ipilimumab (Yervoy).
[0056] In some embodiments, the first treatment comprises a combination of ICIs selected from the group consisting of pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo) atezolizumab (Tecentriq), avelumab (Bavencio), durvalumab (Imfinzi) and ipilimumab (Yervoy).
[0057] In some embodiments, if the percentile score is less than the first predetermined threshold, the subject is not recommended for a second treatment.
[0058] In some embodiments, the second treatment comprises a non-ICI.
[0059] In some embodiments, the second treatment comprises any treatment other than a PD-1 inhibitor, a PDL-1 inhibitor, and a CTLA-4 inhibitor.
[0060] In some embodiments, the second treatment includes any treatment other than pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo) atezolizumab (Tecentriq), avelumab (Bavencio), durvalumab (Imfinzi), and ipilimumab (Yervoy).
[0061] In some embodiments, the second treatment comprises a treatment selected from the group consisting of surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, hormone therapy, stem cell transplantation, cytokine therapy, gene therapy, cell therapy, phototherapy, heat therapy, and sound therapy.
[0062] In some embodiments, the method of quantifying the diversity of at least one HLA allele pair further comprises determining RNA expression levels of one or more HLA allele pairs, obtaining an RNA expression level score of the at least one HLA allele pair relative to the expression levels of the one or more HLA allele pairs, determining a weighted percentile score of the at least one HLA allele pair relative to a distribution of alignment scores of the one or more HLA allele pairs based on the RNA expression level score of the at least one HLA allele pair, and comparing the weighted percentile score to a second predetermined threshold.
[0063] In some embodiments, the method of quantifying the diversity of at least one HLA allele pair further comprises determining the RNA expression level of one or more HLA allele pairs.
[0064] In some embodiments, the method of quantifying the diversity of at least one HLA allele pair further comprises determining the RNA expression levels of one or more HLA allele pairs and obtaining an RNA expression level score of the at least one HLA allele pair relative to the expression levels of the one or more HLA allele pairs.
[0065] In some embodiments, the method of quantifying the diversity of at least one HLA allele pair further comprises determining an RNA expression level of one or more HLA allele pairs, obtaining an RNA expression level score of the at least one HLA allele pair relative to the expression levels of the one or more HLA allele pairs, and determining a weighted percentile score of the at least one HLA allele pair.
[0066] In some embodiments, the method of quantifying the diversity of at least one HLA allele pair further comprises determining RNA expression levels of one or more HLA allele pairs, obtaining an RNA expression level score of the at least one HLA allele pair relative to the expression levels of the one or more HLA allele pairs, and determining a weighted percentile score of the at least one HLA allele pair based on the RNA expression level score of the at least one HLA allele pair.
[0067] In some embodiments, the method of quantifying the diversity of at least one HLA allele pair further comprises determining RNA expression levels of one or more HLA allele pairs, obtaining an RNA expression level score of the at least one HLA allele pair relative to the expression levels of the one or more HLA allele pairs, and determining a weighted percentile score of the at least one HLA allele pair relative to a distribution of alignment scores of the one or more HLA allele pairs based on the RNA expression level score of the at least one HLA allele pair.
[0068] In some embodiments, the method of quantifying the diversity of at least one HLA allele pair further comprises determining RNA expression levels of one or more HLA allele pairs, obtaining an RNA expression level score of the at least one HLA allele pair relative to the expression levels of the one or more HLA allele pairs, determining a weighted percentile score of the at least one HLA allele pair relative to a distribution of alignment scores of the one or more HLA allele pairs based on the RNA expression level score of the at least one HLA allele pair, and comparing the weighted percentile score to a second predetermined threshold.
[0069] In some embodiments, RNA expression levels of HLA alleles can be determined and quantified using one or more of microarray analysis, real-time PCR, quantitative real-time PCR, reverse transcription PCR, RNA sequencing, NextGen sequencing, tiling arrays, Northern blotting, SAGE, in situ hybridization, and expressed sequence tags, as well as other RNA quantification techniques known in the art.
[0070] In some embodiments, protein expression levels of HLA alleles can be determined and quantified using one or more of Western blotting, mass spectrometry, and other protein quantification techniques known in the art.
[0071] In some embodiments, if the weighted percentile score is equal to or greater than the second predetermined threshold, the subject is recommended the first treatment.
[0072] In some embodiments, if the weighted percentile score is less than a second predetermined threshold, the subject is recommended for a second treatment.
[0073] In some embodiments, the first predetermined threshold is 50%. In some embodiments, the first predetermined threshold is 75%. In some embodiments, the first predetermined threshold is 25%. In some embodiments, the first predetermined threshold is 50%, where an embodiment of the method of quantifying HLA diversity includes at least one additional parameter. In some embodiments, the first predetermined threshold is 75%, where an embodiment of the method of quantifying HLA diversity includes at least one additional parameter. In some embodiments, the first predetermined threshold is 25%, where an embodiment of the method of quantifying HLA diversity includes at least one additional parameter. In some embodiments, the first predetermined threshold is in the range of about 10% to about 90%.
[0074] In some embodiments, the second predetermined threshold is 50%. In some embodiments, the second predetermined threshold is 75%. In some embodiments, the second predetermined threshold is 25%. In some embodiments, the second predetermined threshold is 50%, where an embodiment of the method of quantifying HLA diversity includes at least one additional parameter. In some embodiments, the second predetermined threshold is 75%, where an embodiment of the method of quantifying HLA diversity includes at least one additional parameter. In some embodiments, the second predetermined threshold is 25%, where an embodiment of the method of quantifying HLA diversity includes at least one additional parameter. In some embodiments, the second predetermined threshold is in the range of about 10% to about 90%.
[0075] In some embodiments, the first treatment comprises an immune checkpoint inhibitor (ICI). In some embodiments, the ICI stimulates cytotoxic lymphocyte activity against tumor and / or cancer cells.
[0076] In some embodiments, the first treatment comprises an ICI selected from the group consisting of a PD-1 inhibitor, a PDL-1 inhibitor, and a CTLA-4 inhibitor.
[0077] In some embodiments, the first treatment comprises one or more ICIs selected from the group consisting of a PD-1 inhibitor, a PDL-1 inhibitor, and a CTLA-4 inhibitor.
[0078] In some embodiments, the first treatment comprises a combination of ICIs selected from the group consisting of a PD-1 inhibitor, a PDL-1 inhibitor, and a CTLA-4 inhibitor.
[0079] In some embodiments, the first treatment comprises an ICI selected from the group consisting of pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo) atezolizumab (Tecentriq), avelumab (Bavencio), durvalumab (Imfinzi), and ipilimumab (Yervoy).
[0080] In some embodiments, the first treatment comprises one or more ICIs selected from the group consisting of pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo) atezolizumab (Tecentriq), avelumab (Bavencio), durvalumab (Imfinzi) and ipilimumab (Yervoy).
[0081] In some embodiments, the first treatment comprises a combination of ICIs selected from the group consisting of pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo) atezolizumab (Tecentriq), avelumab (Bavencio), durvalumab (Imfinzi) and ipilimumab (Yervoy).
[0082] In some embodiments, the second treatment comprises a non-ICI.
[0083] In some embodiments, the second treatment comprises any treatment other than a PD-1 inhibitor, a PDL-1 inhibitor, and a CTLA-4 inhibitor.
[0084] In some embodiments, the second treatment includes any treatment other than pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo) atezolizumab (Tecentriq), avelumab (Bavencio), durvalumab (Imfinzi), and ipilimumab (Yervoy).
[0085] In some embodiments, the second treatment comprises a treatment selected from the group consisting of surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, hormone therapy, stem cell transplantation, cytokine therapy, gene therapy, cell therapy, phototherapy, heat therapy, and sound therapy.
[0086] In some embodiments, if the first predetermined threshold is 50%, the subject is further recommended to receive a first additional treatment. In some embodiments, if the first predetermined threshold is 75%, the subject is further recommended to receive a first additional treatment. In some embodiments, if the first predetermined threshold is 25%, the subject is further recommended to receive a first additional treatment. In some embodiments, the first predetermined threshold is 50%, where an embodiment of the method of quantifying HLA diversity includes at least one additional parameter, and the subject is further recommended to receive a first additional treatment. In some embodiments, the first predetermined threshold is 75%, where an embodiment of the method of quantifying HLA diversity includes at least one additional parameter, and the subject is further recommended to receive a first additional treatment. In some embodiments, the first predetermined threshold is 25%, where an embodiment of the method of quantifying HLA diversity includes at least one additional parameter, and the subject is further recommended to receive a first additional treatment. In some embodiments, the first predetermined threshold is in the range of about 10% to about 90%.
[0087] In some embodiments, the first additional treatment comprises an ICI selected from the group consisting of a PD-1 inhibitor, a PDL-1 inhibitor, and a CTLA-4 inhibitor.
[0088] In some embodiments, the first additional treatment comprises one or more ICIs selected from the group consisting of a PD-1 inhibitor, a PDL-1 inhibitor, and a CTLA-4 inhibitor.
[0089] In some embodiments, the first additional treatment comprises a combination of ICIs selected from the group consisting of a PD-1 inhibitor, a PDL-1 inhibitor, and a CTLA-4 inhibitor.
[0090] In some embodiments, the first additional treatment comprises an ICI selected from the group consisting of pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo) atezolizumab (Tecentriq), avelumab (Bavencio), durvalumab (Imfinzi), and ipilimumab (Yervoy).
[0091] In some embodiments, the first additional treatment comprises one or more ICIs selected from the group consisting of pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo) atezolizumab (Tecentriq), avelumab (Bavencio), durvalumab (Imfinzi) and ipilimumab (Yervoy).
[0092] In some embodiments, the first additional treatment comprises a combination of ICIs selected from the group consisting of pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo) atezolizumab (Tecentriq), avelumab (Bavencio), durvalumab (Imfinzi) and ipilimumab (Yervoy).
[0093] In some embodiments, if the second predetermined threshold is 50%, the subject is further recommended to receive a second additional treatment. In some embodiments, if the second predetermined threshold is 75%, the subject is further recommended to receive a second additional treatment. In some embodiments, if the second predetermined threshold is 25%, the subject is further recommended to receive a second additional treatment. In some embodiments, the second predetermined threshold is 50%, where an embodiment of the method of quantifying HLA diversity includes at least one additional parameter, and the subject is further recommended to receive a second additional treatment. In some embodiments, the second predetermined threshold is 75%, where an embodiment of the method of quantifying HLA diversity includes at least one additional parameter, and the subject is further recommended to receive a second additional treatment. In some embodiments, the second predetermined threshold is 25%, where an embodiment of the method of quantifying HLA diversity includes at least one additional parameter, and the subject is further recommended to receive a second additional treatment. In some embodiments, the second predetermined threshold is in the range of about 10% to about 90%.
[0094] In some embodiments, the second additional treatment comprises a non-ICI.
[0095] In some embodiments, the second additional treatment comprises any treatment other than a PD-1 inhibitor, a PDL-1 inhibitor, and a CTLA-4 inhibitor.
[0096] In some embodiments, the second additional treatment includes any treatment other than pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo) atezolizumab (Tecentriq), avelumab (Bavencio), durvalumab (Imfinzi), and ipilimumab (Yervoy).
[0097] In some embodiments, the second treatment comprises a treatment selected from the group consisting of surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, hormone therapy, stem cell transplantation, cytokine therapy, gene therapy, cell therapy, phototherapy, heat therapy, and sound therapy.
[0098] In some embodiments of the methods of quantifying the diversity of at least one HLA allele pair, the quantifying is repeated over time to determine whether there is a change in the percentile score relative to a first predetermined threshold.
[0099] In some embodiments of the methods of quantifying the diversity of at least one HLA allele pair, the quantification is repeated over time to determine whether there is a change in the percentile score relative to the second predetermined threshold.
[0100] In some embodiments, assessment of TCR clonality is included in the HLA diversity analysis.
[0101] In some embodiments, a method of determining the predicted efficacy of a cancer treatment in a patient comprises calculating a hazard ratio for an HLA allele pair in the patient, where the hazard ratio reflects the allelic diversity of the HLA allele pair in the patient, and comparing the hazard ratio to a predetermined threshold, where a hazard ratio above the predetermined threshold indicates that the patient is predicted to have a high efficacy against the cancer treatment and a hazard ratio below the predetermined threshold indicates that the patient is predicted to have a low efficacy against the cancer treatment.
[0102] As used herein, "hazard ratio" (HR) is the probability of a "hazard" (e.g., disease, infirmity, death, non-response to treatment, etc.) for a population, determined as a statistically-based correlation between the diversity of HLA alleles and one or more additional parameters as set forth herein. For example, in the context of responsiveness to anti-cancer / tumor treatment, a lower hazard ratio indicates a greater response to the treatment, and a higher hazard ratio indicates a lesser response to the treatment.
[0103] In some embodiments, methods of determining the predicted efficacy of a cancer treatment in a patient are provided.
[0104] In some embodiments, the method of determining the predicted efficacy of a cancer treatment in a patient comprises calculating a hazard ratio for an HLA allele pair in the patient.
[0105] In some embodiments, the method of determining the predicted efficacy of a cancer treatment in a patient comprises calculating a hazard ratio for an HLA allele pair in the patient, where the hazard ratio reflects the allelic diversity of the HLA allele pair in the patient.
[0106] In some embodiments, a method of determining a predicted efficacy of a cancer treatment in a patient comprises calculating a hazard ratio for an HLA allele pair in the patient, where the hazard ratio reflects the allelic diversity of the HLA allele pair in the patient, and comparing the hazard ratio to a predetermined threshold.
[0107] In some embodiments, a method of determining the predicted efficacy of a cancer treatment in a patient includes calculating a hazard ratio for an HLA allele pair in the patient, where the hazard ratio reflects the allelic diversity of the HLA allele pair in the patient, and comparing the hazard ratio to a predetermined threshold, where a hazard ratio above the predetermined threshold indicates that the patient is predicted to have a high efficacy for the cancer treatment.
[0108] In some embodiments, a method of determining the predicted efficacy of a cancer treatment in a patient comprises calculating a hazard ratio for an HLA allele pair in the patient, where the hazard ratio reflects the allelic diversity of the HLA allele pair in the patient, and comparing the hazard ratio to a predetermined threshold, where a hazard ratio below the predetermined threshold indicates that the patient is predicted to have a low efficacy against the cancer treatment.
[0109] In some embodiments of the methods of determining the predicted efficacy of a cancer treatment in a patient, the cancer is a tumor.
[0110] In some embodiments of the methods of determining the predicted efficacy of a cancer treatment in a patient, the cancer is a tumor and the method further comprises measuring a tumor burden score of the patient.
[0111] In some embodiments of the methods of determining the predicted efficacy of a cancer treatment in a patient, the cancer is a tumor and the method further includes measuring the patient's tumor burden score as a factor in determining the efficacy of the cancer treatment and comparing the tumor burden score to a predetermined threshold. EXAMPLES
[0112] The following examples are non-limiting and other variations within the skill of the art are contemplated.
[0113] Example 1 HLA diversity and heterozygosity In this example, the clinical utility of the HLA diversity score in combination with HLA heterozygosity was determined. The feasibility of using the HLA diversity score as a biomarker to predict patient response to ICI treatment based on HLA heterozygosity. To test the potential of CTLA-4, we selected a cohort of 110 patients with metastatic melanoma treated with CTLA-4 (Van Allen, E., et al., (2015) Science, Vol. 350, No. 6257, pp. 207-211, 2015).
[0114] When classifying patients based solely on HLA heterozygosity using the Chowell method (Chowell, D., et al., ScienceVol.359, No.6375, pp.582-587, 2018), the two patient groups, those determined to be HLA heterozygous at all loci and those determined to be homozygous at at least one locus, did not show a statistically significant difference in survival (p=0.99; HR=1 (95% confidence interval (CI)=0.60-1.68); Figure 2A). Thus, simply measuring whether a patient was homozygous or heterozygous for an HLA allele did not correlate well with the patient's survival after treatment.
[0115] Meanwhile, using an embodiment of the method described herein, a diversity score was calculated for each HLA gene of the same patient population based on the percentile of the alignment score of a given pair of HLA alleles. For each patient, three diversity scores were calculated, one each for HLA-A, HLA-B, and HLA-C, to determine how different their alleles are from each other. The patients were then classified into two groups: a first group with at least one HLA locus within the top 20% diversity, and a second group with the bottom 80% HLA diversity at all three HLA-A, HLA-B, and HLA-C loci.
[0116] In contrast to the Chowell method, when the method described herein for quantifying HLA diversity scores was used to classify patients into those with the top 20% diversity score at at least one locus (n=50) and those with the bottom 80% diversity score at all loci (n=60), the two patient groups showed statistically significantly different overall survival (p<0.01, HR=2.01 (95%CI=1.28-3.19); Figure 2B).
[0117] These data demonstrate the applicability of the methods and systems described herein to differentiate patients based on HLA heterozygosity using HLA diversity scores, and the utility of this approach as a biomarker for predicting patient response to ICI treatment.
[0118] Example 2 HLA diversity, HLA heterozygosity, and TMB In this example, the clinical utility of HLA diversity scores in combination with HLA heterozygosity and tumor mutation burden (TMB) was determined.
[0119] Realization of using HLA diversity scores as biomarkers to predict patient response to ICI treatment based on HLA heterozygozity and TMB To test the possibility, we used publicly available data on a cohort of 61 patients.
[0120] When using the Chowell method (Chowell, D., et al., Science,Vol.359, No.6375, pp.582-587, 2018) to classify patients based on HLA heterozygosity and TMB, 2 The two patient groups, those HLA heterozygous at all loci and those homozygous at at least one locus, did not show a statistically significant difference in survival (p=0.19; HR=1.55 (95% CI=0.79-3.03); Figure 3A).
[0121] According to an embodiment of the method described herein, a diversity score was calculated for each HLA gene based on the percentile of the alignment score of a given pair of HLA alleles. For each patient, three diversity scores were calculated, one each for HLA-A, HLA-B, and HLA-C. Patients were then classified into two groups: the first group had at least one HLA locus within the top 20% diversity, and the second group had the bottom 80% HLA diversity at all three HLA-A, HLA-B, and HLA-C loci.
[0122] In contrast to the Chowell method, when the method described herein for quantifying HLA diversity score was used to classify patients into those with the top 20% diversity score at at least one locus and high TMB (n=28) and those with the bottom 80% diversity score at all loci and low TMB (n=33), the two patient groups showed statistically significantly different overall survival (p<0.002, HR=2.69 (95%CI=1.39-5.21); Figure 3B).
[0123] These data demonstrate the applicability of the methods and systems described herein to quantify HLA diversity scores and differentiate patients based on HLA heterozygosity and TMB, as well as their utility as biomarkers to predict patient response to ICI treatment.
[0124] Example 3 TMB and overall survival In this example, the correlation between TMB and overall survival was evaluated.
[0125] We used publicly available data on a cohort of 110 patients. Patients were stratified into two groups, high and low TMB groups, using the median TMB level (total mutation load 200 per patient) as a cutoff.
[0126] High TMB patients showed higher overall survival compared to low TMB patients (p=0.15, HR=1.37 (95%CI=0.89-2.12); Figure 4). This may be because higher TMB increases the likelihood of neoantigen recognition by cytotoxic T cells.
[0127] Example 4 The first patient presents with a tumor in the prostate. The HLA allele variants of this patient are analyzed. This patient has HLA allele A with a similarity percentage of 99.74%. * 01:01 and A * 01:02, which means they are more similar than 99.74% of all known pairs of HLA-A alleles, suggesting a very high similarity. This patient is ranked as having a low probability of success with CAR-T therapy due to the similarity of HLA alleles.
[0128] The second patient presents with a tumor in the prostate. The HLA allele variants of this patient are analyzed. This patient has HLA allele A, which has a similarity percentage of only 17.97%. * 01:01 and A * 24:34, suggesting that their alleles have low similarity and high diversity. Due to the diversity between HLA alleles, this patient is ranked as having a relatively high probability of successful tumor treatment with CAR-T therapy compared to the first patient.
[0129] Example 5 A patient presents with a tumor and the diversity of HLA alleles is measured to determine whether various treatments are likely to be successful. Instead of simply scoring the diversity of a patient's HLA alleles as within two categories of heterozygous or homozygous for the HLA alleles, a more complex analysis is performed. The HLA alleles of each allele from the patient are then compared to the HLA alleles of the patient. The sequences of A, B, C, E, F, G, H, J, K, L, DP, DQ and DR genes are determined. The percent identity of each allele pair from each gene is calculated to determine an overall score. Then, a diversity score is calculated for each allele pair in each gene by calculating the percentile of the alignment score of a given pair of HLA alleles in the distribution of all pairwise alignment scores. From this score, a pre-set cutoff is used to divide the patients and calculate a hazard ratio based on survival rate. Statistical analysis is performed using a log-rank test or Wilcoxon rank sum test with or without Bonferroni correction. This score results in an overall similarity score of 14.4%, which means that the alleles are not very similar to each other. This high diversity of the patient's HLA genes can then be used to determine that the patient has a tendency to respond relatively well to anti-tumor therapy.
[0130] Example 6 A patient presents with a tumor and the diversity of HLA alleles is measured to determine whether various treatments are likely to be successful. Instead of simply scoring the diversity of a patient's HLA alleles as within two categories of heterozygous or homozygous for the HLA alleles, a more complex analysis is performed. The HLA alleles of each allele from the patient are then compared to the HLA alleles of the patient. The sequences of A, B, C, E, F, G, H, J, K, L, DP, DQ, and DR genes are determined. As mentioned above, each HLA class I gene has eight exons, but exon 2 (corresponding to the alpha 1 domain) and exon 3 (corresponding to the alpha 2 domain) code for the binding core of the HLA molecule and are the most polymorphic regions. This is shown in Figure 1A, Figure 1B, and Figure 1C for the HLA-A, HLA-B, and HLA-C genes, respectively. The alignment scores of each exon 2 and exon 3 domain from each allele pair are given more weight in the calculation of the overall alignment score. A diversity score is then calculated for each allele pair in each gene by calculating the percentile of the alignment score of a given pair of HLA alleles in the distribution of all pairwise alignment scores. From this score, a hazard ratio is calculated using the allele diversity score cutoff. Statistical analysis is performed using the log-rank test or the Wilcoxon rank sum test with or without Bonferroni correction. This score results in an overall similarity score of 70.4%, meaning that the alleles are fairly similar to each other. This relatively low diversity of the patient's HLA genes can then be used to determine that the patient has a relatively low propensity for response to antitumor therapy.
[0131] Example 7 A patient presents with a tumor and the diversity of HLA alleles is measured to determine whether various treatments are likely to be successful. Instead of simply scoring the diversity of a patient's HLA alleles as within two categories of heterozygous or homozygous for the HLA alleles, a more complex analysis is performed. The HLA alleles of each allele from the patient are then compared to the HLA alleles of the patient. The sequences of A, B, C, E, F, G, H, J, K, L, DP, DQ and DR genes are determined. As mentioned above, each HLA class I gene has 8 exons, but exon 2 (corresponding to alpha 1 domain) and exon 3 (corresponding to alpha 2 domain) code the binding core of HLA molecule and are the most polymorphic regions. This is shown in Figure 1A, Figure 1B and Figure 1C for HLA-A, HLA-B and HLA-C genes, respectively. The alignment scores of each exon 2 and exon 3 domain from each allele pair are given more weight in the calculation of the overall alignment score. Then, a diversity score is calculated for each allele pair in each gene by calculating the percentile of the alignment score of a given pair of HLA alleles in the distribution of all pairwise alignment scores. From this score, a hazard ratio is calculated using an allele diversity score cutoff. The allelic diversity score is used in combination with the RNA expression level of each allele of the HLA A, B, C, E, F, G, H, J, K, L, DP, DQ, and DR genes calculated from the RNA expression data from the patient. To calculate the overall diversity score, more weight is given to the allelic diversity score of the highly expressed alleles of the HLA genes as a predictor. Thus, the allelic diversity score from the highly expressed alleles of the HLA genes contributes more to the hazard ratio. Statistical analysis is performed using the log-rank test or the Wilcoxon rank sum test with or without Bonferroni correction. This score results in an overall similarity score of 91.4%, which means that the alleles are quite similar to each other. This relatively low diversity of the patient's HLA genes can then be used to determine that the patient has a tendency to a relatively low response to antitumor therapy.
[0132] Example 8 A patient presents with a tumor and the diversity of HLA alleles is measured to determine whether various treatments are likely to be successful. Instead of simply scoring the diversity of a patient's HLA alleles as within two categories of heterozygous or homozygous for the HLA alleles, a more complex analysis is performed. The HLA alleles of each allele from the patient are then compared to the HLA alleles of the patient. The sequences of A, B, C, E, F, G, H, J, K, L, DP, DQ, and DR genes are determined. As mentioned above, each HLA class I gene has eight exons, but exon 2 (corresponding to the alpha 1 domain) and exon 3 (corresponding to the alpha 2 domain) code for the binding core of the HLA molecule and are the most polymorphic regions. This is shown in Figure 1A, Figure 1B, and Figure 1C for the HLA-A, HLA-B, and HLA-C genes, respectively. A diversity score is generated for each individual HLA gene alone (HLA A, B, C, E, F, G, H, J, K, L, DP, DQ, and DR genes). A combination of the scores of the HLA A, B, C, E, F, G, H, J, K, L, DP, DQ, and DR genes is used to achieve a single score for each patient. The scores are weighted equally. The analysis is optionally combined with a weighting factor calculated for one or more single gene scores. Weighting factors are based on the relative expression of genes in tissues as determined, for example, by microarray, RNA sequencing analysis, etc. Single gene or HLA A, B, C, E, F, G, H, J, K, L, DP, DQ, and DR gene composite scores are also combined with the TMB score to arrive at a composite score. Additionally, heterozygosity scores are weighted or combined with HLA zygosity (homozygous=0, most distinct=1).
[0133] Example 9 A patient presents with a tumor and the diversity of HLA alleles is measured to determine whether various treatments are likely to be successful. Instead of simply scoring the diversity of a patient's HLA alleles as within two categories of heterozygous or homozygous for the HLA alleles, a more complex analysis is performed. The HLA alleles of each allele from the patient are then compared to the HLA alleles of the patient. The sequences of A, B, C, E, F, G, H, J, K, L, DP, DQ and DR genes are determined. As mentioned above, each HLA class I gene has 8 exons, but exon 2 (corresponding to alpha 1 domain) and exon 3 (corresponding to alpha 2 domain) code the binding core of HLA molecule and are the most polymorphic regions. This is shown in Figure 1A, Figure 1B and Figure 1C for HLA-A, HLA-B and HLA-C genes, respectively. The alignment scores of each exon 2 and exon 3 domain from each allele pair are given more weight in the calculation of the overall alignment score. A diversity score is then calculated for each allele pair in each gene by calculating the percentile of the alignment score of a given pair of HLA alleles in the distribution of all pairwise alignment scores. From this score, the allele diversity score is used to calculate the hazard ratio. The allele diversity score is used in combination with one or more additional parameters, including HLA zygosity, familial inheritance, hereditary inheritance, Mendelian inheritance, non-Mendelian inheritance, other genetic associations and correlations. To calculate the overall diversity score, one or more additional parameters (e.g., non-Mendelian inheritance) are given more weight based on the degree of contribution as a predictor. Statistical analysis is performed using a log-rank test or a Wilcoxon rank sum test with or without Bonferroni correction. This score results in an overall similarity score of 5.2%, which means that the alleles are not very similar to each other. This relatively low diversity of the patient's HLA genes can then be used to determine that the patient has a tendency to be relatively responsive to anti-tumor therapy.
[0134] Example 10 A patient presents with a tumor and the diversity of HLA alleles is measured to determine whether various treatments are likely to be successful. Instead of simply scoring the diversity of a patient's HLA alleles as within two categories of heterozygous or homozygous for the HLA alleles, a more complex analysis is performed. The HLA alleles of each allele from the patient are then compared to the HLA alleles of the patient. The sequences of A, B, C, E, F, G, H, J, K, L, DP, DQ and DR genes are determined. As mentioned above, each HLA class I gene has 8 exons, but exon 2 (corresponding to alpha 1 domain) and exon 3 (corresponding to alpha 2 domain) code the binding core of HLA molecule and are the most polymorphic regions. This is shown in Figure 1A, Figure 1B and Figure 1C for HLA-A, HLA-B and HLA-C genes, respectively. The alignment scores of each exon 2 and exon 3 domain from each allele pair are given more weight in the calculation of the overall alignment score. A diversity score is then calculated for each allele pair in each gene by calculating the percentile of the alignment score of a given pair of HLA alleles in the distribution of all pairwise alignment scores. From this score, the allele diversity score is used to calculate a hazard ratio. The allele diversity score is used in combination with one or more additional parameters, including the mutation load of the patient's tumor. To calculate the overall diversity score, one or more additional parameters are given more weight based on their degree of contribution as predictors (e.g., more weight is given to the mutation load). Statistical analysis is performed using the log-rank test or Wilcoxon rank sum test with or without Bonferroni correction. This score results in an overall similarity score of 3.1%, which means that the alleles are not very similar to each other. This relatively low diversity of the patient's HLA genes can then be used to determine that the patient has a tendency to a relatively high response to antitumor therapy.
[0135] Example 11 A patient presents with a tumor and the diversity of HLA alleles is measured to determine whether various treatments are likely to be successful. Instead of simply scoring the diversity of a patient's HLA alleles as within two categories of heterozygous or homozygous for the HLA alleles, a more complex analysis is performed. The HLA alleles of each allele from the patient are then compared to the HLA alleles of the patient. The sequences of A, B, C, E, F, G, H, J, K, L, DP, DQ and DR genes are determined. As mentioned above, each HLA class I gene has 8 exons, but exon 2 (corresponding to alpha 1 domain) and exon 3 (corresponding to alpha 2 domain) code the binding core of HLA molecule and are the most polymorphic regions. This is shown in Figure 1A, Figure 1B and Figure 1C for HLA-A, HLA-B and HLA-C genes, respectively. The alignment scores of each exon 2 and exon 3 domain from each allele pair are given more weight in the calculation of the overall alignment score. A diversity score is then calculated for each allele pair in each gene by calculating the percentile of the alignment score of a given pair of HLA alleles in the distribution of all pairwise alignment scores. From this score, the allele diversity score is used to calculate the hazard ratio. The allelic diversity score is used in combination with one or more additional parameters including RNA and / or protein expression levels of each allele of the patient's HLA A, B, C, E, F, G, H, J, K, L, DP, DQ, and DR genes of the alleles calculated from the RNA and / or protein expression data from the patient, HLA zygosity, familial inheritance, hereditary inheritance, Mendelian inheritance, non-Mendelian inheritance, other genetic associations and correlations, as well as in combination with the mutational burden of the patient's tumor. To calculate the overall diversity score, as a predictor, more weight is given to one or more additional parameters based on the degree of contribution (e.g., more weight is given to the allelic diversity score of the high expression alleles of the HLA genes). Statistical analysis is performed using a log-rank test or a Wilcoxon rank sum test with or without Bonferroni correction. This score results in an overall similarity score of 7.4%, which means that the alleles are not very similar to each other. This relatively low diversity of the patient's HLA genes can then be used to determine that the patient has a tendency to be relatively responsive to anti-tumor therapy.
[0136] Although the present disclosure is in the context of certain embodiments and examples, those skilled in the art will understand that the present disclosure extends beyond the specifically disclosed embodiments to other alternative embodiments and / or use of the embodiments, as well as obvious modifications and equivalents thereof. In addition, while some variations of the embodiments have been shown and described in detail, other modifications that are within the scope of the present disclosure will be readily apparent to those skilled in the art based on the present disclosure. It is also contemplated that various combinations or subcombinations of specific features and aspects of the embodiments may be made and still fall within the scope of the present disclosure. It should be understood that various features and aspects of the disclosed embodiments can be combined or substituted with each other to form various modes or embodiments of the present disclosure. Therefore, it is intended that the scope of the present disclosure herein should not be limited by the specific disclosed embodiments described above. The present invention provides, for example, the following items. (Item 1) 1. A method of quantifying diversity of at least one HLA allele pair in a subject, comprising obtaining DNA sequences of one or more HLA allele pairs in said subject; comparing said DNA sequences of said one or more HLA allele pairs to obtain an alignment score; obtaining a distribution of said alignment scores for said one or more HLA allele pairs; determining a percentile score for said at least one HLA allele pair relative to said distribution of alignment scores for all HLA allele pairs; A method comprising: (Item 2) 2. The method of claim 1, further comprising comparing the percentile score to a first predetermined threshold. (Item 3) 2. The method of claim 1, wherein the at least one HLA allele pair comprises any pair of HLA A, B, C, E, F, G, H, J, K, L, DP, DQ, and DR alleles. (Item 4) 2. The method of claim 1, wherein if the percentile score is equal to or greater than a first predetermined threshold, the subject is recommended a first treatment. (Item 5) 2. The method of claim 1, wherein if the percentile score is less than a first predetermined threshold, the subject is recommended for a second treatment. (Item 6) determining an expression level of said one or more HLA allele pairs; obtaining an expression level score for said at least one HLA allele pair relative to said expression levels of said one or more HLA allele pairs; determining a weighted percentile score for the at least one HLA allele pair relative to the distribution of alignment scores for the one or more HLA allele pairs based on the expression level score for the at least one HLA allele pair; comparing the weighted percentile score to a second predetermined threshold; The method of claim 1, further comprising: (Item 7) 7. The method of claim 6, wherein if the weighted percentile score is equal to or greater than the second predetermined threshold, the subject is recommended a first treatment. (Item 8) 7. The method of claim 6, wherein if the weighted percentile score is less than the second predetermined threshold, the subject is recommended for a second treatment. (Item 9) 3. The method of claim 2, wherein the first predetermined threshold is about 75%. (Item 10) 7. The method of claim 6, wherein the second predetermined threshold is about 75%. (Item 11) 5. The method of claim 4, wherein the first treatment comprises an ICI. (Item 12) 6. The method of item 5, wherein the second treatment comprises a non-ICI. (Item 13) 3. The method of claim 2, wherein if the first predetermined threshold is 50%, the subject is further recommended a first additional treatment. (Item 14) 7. The method of claim 6, wherein if the second predetermined threshold is 50%, the subject is further recommended a second additional treatment. (Item 15) 7. The method of claim 6, wherein the expression level is an RNA expression level, a protein expression level, or both. (Item 16) The method of any one of the preceding items, wherein the quantifying is repeated over time to determine whether there is a change in the percentile score relative to the first predetermined threshold. (Item 17) The method of any one of the preceding items, wherein the quantifying is repeated over time to determine whether there is a change in the percentile score relative to the second predetermined threshold. (Item 18) The method of any one of the preceding items, wherein said quantifying comprises assessment of TCR clonality. (Item 19) 1. A method for determining the predicted efficacy of a cancer treatment in a patient, comprising: calculating a hazard ratio for an HLA allele pair in the patient, the hazard ratio reflecting the allelic diversity of the HLA allele pair in the patient; comparing the hazard ratio to a predetermined threshold, a hazard ratio above the predetermined threshold indicating that the patient is predicted to have a high efficacy to the cancer treatment and a hazard ratio below the predetermined threshold indicating that the patient is predicted to have a low efficacy to the cancer treatment; A method comprising: (Item 20) 20. The method of claim 19, wherein the cancer is a tumor, and the method further comprises measuring the patient's tumor burden score as a factor in determining the effectiveness of the cancer treatment, and comparing the tumor burden score to a predetermined threshold.
Claims
[Claim 1] The invention described in the specification.
